Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10157982 | Vaccine | 2018 | 9 Pages |
Abstract
No effective human vaccine against Toxoplasma gondii (T. gondii) has yet been developed; however, a protective vaccine using immunogenic peptides in a safe delivery vehicle system offers promise. Here, we employed bioinformatics to design a multimeric recombinant T. gondii vaccine using predicted T and B cell epitopes of SAG1, AMA1, ROP2, and GRA4 proteins based on their binding capabilities to common major histocompatibility complex (MHC) molecules. Furthermore, we encapsulated the expressed protein in poly lactic-co-glycolic acid (PLGA) nanoparticles as a delivery vehicle and also used alum as an adjuvant to determine the vaccine potency of this multimeric antigen. BALB/c mice were vaccinated and then challenged with T. gondii RH strain, and the survival rate and cytokine profiles were studied. Mice vaccinated with the multi-epitope-based vaccine, both with and without PLGA, had greater Th1 immune responses, survival rates, specific antibody titers, and IFN-γ and IL-2 levels than controls, while the alum-adsorbed vaccine stimulated a Th2-type humoral immune response.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Mona Roozbehani, Reza Falak, Mohsen Mohammadi, Andrew Hemphill, Elham Razmjou, Ahmad reza Meamar, Leila Masoori, Majid Khoshmirsafa, Maryam Moradi, Mohammad Javad Gharavi,